Using antioxidant-rich media to improve embryo quality in IVF
Antioxidants-enriched Single-step vs Global Total Single-step Embryo Culture Media: Effect on Blastocyst Euploidy Rates.
NA · ART Fertility Clinics LLC · NCT06261671
This study is testing if using a special culture solution with antioxidants can help improve the quality of embryos for people undergoing IVF.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 500 (estimated) |
| Ages | 18 Years to 43 Years |
| Sex | All |
| Sponsor | ART Fertility Clinics LLC (other) |
| Locations | 1 site (Abu Dhabi, Abu Dhabi Emirate) |
| Trial ID | NCT06261671 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effect of antioxidant-enriched culture media on the euploidy rates of embryos during in vitro fertilization (IVF). It aims to address the negative impact of reactive oxidative species (ROS) on embryo development by utilizing a culture medium that contains higher concentrations of antioxidants. The trial will involve a randomized approach using sibling oocytes from patients undergoing assisted reproductive technology cycles. The primary goal is to determine if this improved culture condition can enhance the quality of embryos suitable for implantation.
Who should consider this trial
Good fit: Ideal candidates are women aged 18-43 undergoing IVF with sufficient oocytes for intracytoplasmic sperm injection (ICSI).
Not a fit: Patients undergoing preimplantation genetic testing for monogenic disorders (PGT-M) or those using testicular sperm will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to higher rates of viable embryos and improved outcomes for patients undergoing IVF.
How similar studies have performed: While few human IVF studies have explored this approach, animal models have shown promising results, indicating potential for success in human applications.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients undergoing assisted reproductive technology cycles when ICSI is indicated. * Patients when Iin vitto fertilization (IVF) is also performed will be included as far as there are enough oocytes for ICSI randomization. However, IVF oocytes will not be used for the study. * Maternal age 18-43 years old. * PGT-A cycles with only trophectoderm biopsies on day 5/6/7. * Patients with more than 6 COCs expected for ICSI. * Body mass index \<35. * Fresh and frozen ejaculated sperm. Exclusion Criteria: * PGT-M cycles * Fresh and frozen testicular sperm.
Where this trial is running
Abu Dhabi, Abu Dhabi Emirate
- ART Fertility Clinics LLC — Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates (RECRUITING)
Study contacts
- Study coordinator: Daniela Nogueira
- Email: daniela.nogueira@artfertilityclinics.com
- Phone: +971504374961
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Infertility, In Vitro Fertilization, Intracytoplasmic sperm injection, Pre - implanttaion genetic diagnosis for aneuploidy, Antioxydante, Culture media, Embryo development, Euploidy